AC
LUCD icon

AlphaCore Capital’s Lucid Diagnostics LUCD Stock Holding History

AlphaCore Capital’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5K Buy
+10,000
New +$12.7K ﹤0.01% 1106

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

AlphaCore Capital's LUCD Position: Q1 2026 in Review

AlphaCore Capital opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 10,000 shares worth $11.5K. The stake represents ﹤0.01% of the portfolio and ranks #1106 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • AlphaCore Capital held 10,000 shares of Lucid Diagnostics worth $11.5K as of Q1 2026.
  • Lucid Diagnostics was a new AlphaCore Capital position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of AlphaCore Capital's portfolio in Q1 2026, its #1106 holding.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.